Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.

Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
weberfr8

/by

Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.

Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
weberfr8

/by

Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab

Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
arcticnovartis

  • Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical data
  • Breast and gastric cancers are among most common types of cancer, accounting together for nearly half a million new cases every year in Europe alone1,2
  • Sandoz is committed to accelerating access to potentially life-changing treatments and continues to strengthen its oncology and supportive care portfolio

Basel, September 18, 2023 —

/by

Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab

Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
arcticnovartis

  • Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical data
  • Breast and gastric cancers are among most common types of cancer, accounting together for nearly half a million new cases every year in Europe alone1,2
  • Sandoz is committed to accelerating access to potentially life-changing treatments and continues to strengthen its oncology and supportive care portfolio

Basel, September 18, 2023 —

/by

Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu

Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
arcticnovartis

  • Die Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.
  • Die Aktionärinnen und Aktionäre stimmen ausserdem einer Herabsetzung des Aktienkapitals im Zusammenhang mit dem Spin-off zu.
  • Die Aktionärinnen und Aktionäre von Novartis und Inhaberinnen und Inhaber der Novartis ADR erhalten durch die Ausschüttung einer Sachdividende eine Sandoz Aktie für jeweils fünf Novartis Aktien oder ein Sandoz ADR für jeweils fünf Novartis ADRs.
/by

Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu

Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
arcticnovartis

  • Die Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.
  • Die Aktionärinnen und Aktionäre stimmen ausserdem einer Herabsetzung des Aktienkapitals im Zusammenhang mit dem Spin-off zu.
  • Die Aktionärinnen und Aktionäre von Novartis und Inhaberinnen und Inhaber der Novartis ADR erhalten durch die Ausschüttung einer Sachdividende eine Sandoz Aktie für jeweils fünf Novartis Aktien oder ein Sandoz ADR für jeweils fünf Novartis ADRs.
/by

Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis

  • Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta® (ofatumumab) and Mayzent® (siponimod)

  • Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS. Remibrutinib is a highly selective, potent oral BTK inhibitor with a potential best-in-class profile1
  • Late-breaking safety data will be presented, including outcomes of COVID-19 in relapsing forms of …
/by

Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs

  • Company previously disclosed settlement agreement in principle and fully provisioned for this resolution

Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has entered a settlement agreement with the Civil Division of the U.S. Department of Justice (DOJ) concerning the Department’s years-long pricing investigation into the U.S. generic drug industry. This settlement is an expected outcome of the resolution the company reached in March 2020 with the DOJ Antitrust Division regarding the same investigation and underlying …

/by

Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs

  • Company previously disclosed settlement agreement in principle and fully provisioned for this resolution

Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has entered a settlement agreement with the Civil Division of the U.S. Department of Justice (DOJ) concerning the Department’s years-long pricing investigation into the U.S. generic drug industry. This settlement is an expected outcome of the resolution the company reached in March 2020 with the DOJ Antitrust Division regarding the same investigation and underlying …

/by

Enabling our associates to work safely on our sites

As a leading healthcare company, Novartis is playing an important part by supporting vaccination to help overcome the pandemic. The safety of all associates, our customers, business partners and the communities where we run our operations remain a top priority for us. As company we have agreed on a long-term strategy supporting the global vaccination efforts and the COVID-19 vaccines are proven to be a powerful tool enabling us to move back to a more regular life.

In countries, where sufficient vaccine is available – and where it is in line with local law and regulations – we …

/by